NEOGENOMICS INC — Director's Dealing 2023

Feb 1, 2023

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2022-12-31

Reporting Person: Sikri Vishal (President, Pharma Services)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-31	Common Stock	L	225	$7.04	Acquired	148680	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$8.42	2029-06-01	Common Stock (319112.0)	319112	Direct

Footnotes

F1: These shares were acquired pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) during the year ended December 31, 2022. The shares were acquired in transactions exempt from Section 16b-3.

F2: On June 1, 2022, Mr. Sikri was granted 193,799 stock options. These options vest ratably over the first two anniversary dates of the grant date.

F3: On June 1, 2022, Mr. Sikri was granted 125,313 stock options. These options vest ratably over the first four anniversary dates of the grant date.